Frontiers in Oncology retracts 2024 sorafenib and tarexib hepatocellular carcinoma paper after authors fail to supply raw data
Frontiers in Oncology has retracted a 2024 paper on sorafenib combined with tarexib for unresectable hepatocellular carcinoma after the authors ...